47 employees
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
2021
$75M
from 5 investors over 5 rounds
Photys Therapeutics raised $75M on September 8, 2022
Investors: Heritage Medical Systems, Omega Funds, Longwood Fund, MPM Capital and 8VC